Our News
Alnylam Publishes 2021 Corporate Responsibility Report
March 16, 2022
Alnylam Pharmaceuticals
At Alnylam, our Corporate Responsibility (CR) work is guided by the theme “Accepting Challenges to Improve the Health of Humanity” and articulates how we approach our work each day. It describes our commitment to tackling unprecedented and complex challenges, taking courageous action, and using our business as a force for good.
We began our CR journey in early 2020 through a combination of assessment and introspection leading to the development of an initial set of priorities for CR and establishing the organizational structures necessary to ensure that our actions matched our intentions, all of which we detailed in our first ever Corporate Responsibility Summary. In 2021, we built on this foundational work by hiring our first dedicated CR Director and formalizing a CR Steering Committee structure that aligned key Working Groups for each of our areas of focus in CR – patients, science, employees, communities, and planet.
Corporate responsibility has been a guiding principle for who we are and how we operate since Alnylam’s inception. In 2021, we integrated corporate responsibility even further into our company’s RNA by addressing health inequities in our communities, advancing efforts to reduce our environmental impact, and strengthening our commitment to diversity, equity, and inclusion. As we continue to drive these efforts forward for our patients, science, employees, communities, and planet, we are also committed to transparently and regularly communicating our progress.” - Yvonne Greenstreet, MBChB, MBA, CEO of Alnylam
Through the hard work of our teams who oversee, develop strategy for, and review reporting and key performance indicators surrounding their individual pillars, we are proud to share our first full Corporate Responsibility Report which you can download here.
Key highlights from this report include:
- Establishment of baseline measures of Alnylam’s environmental impact. In 2021, we launched a comprehensive and ongoing process to quantify and mitigate the company’s greenhouse gas (GHG) emissions and waste management. As a result, we can now assess and disclose its impact on the planet for the first time, including the disclosure of scope 1, 2, and select scope 3 GHG emissions, and align these disclosures with the Global Reporting Initiative (GRI) and Sustainability Accounting and Standards Board (SASB) frameworks.
- Expanded efforts addressing health inequities in local communities. Embedded in our culture is a commitment to tackle barriers to health and healthcare access for all. In 2021, the company launched Alnylam Challengers with a $1 million investment in non-profit partner Acumen America. This community impact initiative advances bold, social enterprises that tackle health inequalities for underrepresented populations and people living in underserved communities.
- Enhancements to Alnylam’s Diversity, Equity, and Inclusion (DEI) plan. We are assessing and enhancing DEI-related policies and actions in all aspects of its operations and interactions. DEI goals are framed around five key focus areas – four internally focused and one externally focused goal to increase diversity in our clinical trials processes.
Our 2021 Corporate Responsibility Report provides more details on the specific actions we're taking and intend to take in 2022 and beyond. We are committed to transparently and regularly committing our progress and will continue to build our CR sophistication as we mature as a company and the world changes around us.
